Syros Pharmaceuticals (SYRS) Misses Q2 EPS by 13c

Syros Pharmaceuticals (NASDAQ: SYRS) reported Q2 EPS of ($0.54), $0.13 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $6.28 million versus the consensus estimate of $4.74 million.

For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Lockheed Martin frontrunner for $3.5B Ultra Maritime deal, sources say - FT
• Elevance (ELV) PT Raised to $482 at Bernstein SocGen